Clinical trials: Other Hematologic Malignant Neoplasms
Non-Hodgkin's Lymphoma (NHL), Multiple Myeloma
Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors
Many tumor cells, in contrast to normal cells, have been shown to require the amino acid glutamine to produce energy for growth and survival.
- Conditions
- Non-Hodgkin's Lymphoma (NHL), Multiple Myeloma, Waldenstrom's Macroglobulinemia (WM), Other B-cell NHL Subtypes, Including WM
- Trial name
- NCT02071888
- Testing
- CB-839, CB-839 and low dose dexamethasone, CB-839, pomalidomide, and low dose dexamethasone
- Where
- 7 sites in United States
- Volunteers
- 25 people
- Sponsor
- Calithera Biosciences, Inc
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant
RATIONALE: Rasburicase may be an effective treatment for graft-versus-host disease caused by a donor stem cell transplant. PURPOSE: This clinical trial is studying how well rasburicase works in preventing graft-versus-host…
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00513474
- Testing
- busulfan, cyclophosphamide, cyclosporin-A
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Massachusetts General Hospital
Leukemia
Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
The goal of this clinical research study is to learn if the combination of azacitidine and vorinostat can help to control AML or MDS better than azacitidine alone. The safety of this drug combination will also be studied.
- Trial name
- NCT00948064
- Testing
- Vorinostat, Azacitidine
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- M.D. Anderson Cancer Center
Drug/Agent Toxicity by Tissue/Organ, Leukemia
Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer
RATIONALE: Keratinocyte growth factor may prevent symptoms of mucositis in patients receiving radiation therapy and chemotherapy.
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00004132
- Testing
- filgrastim, palifermin, cyclophosphamide
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Pediatric Patients, Hematologic Malignancy
TCR Alpha/Beta and CD19-deplete Haplo-HSCT
This is an open label, interventional, non-randomized, phase II trial of TCR alpha/beta and CD19-depeleted allogeneic HCT in pediatric patients with hematologic disease.
- Conditions
- Pediatric Patients, Hematologic Malignancy, Other Hematologic Condition
- Trial name
- NCT05288595
- Testing
- CliniMACS Plus Instrument
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Neoplasms
Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
This study will evaluate the safety, tolerability, and clinical activity of GSK3326595 in participants with relapsed and refractory MDS, chronic myelomonocytic leukemia (CMML), and AML.
- Trial name
- NCT03614728
- Testing
- GSK3326595, 5-Azacitidine
- Where
- 8 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- GlaxoSmithKline
Leukemia, Myelodysplastic Syndromes
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow doctors to give higher doses of…
- Trial name
- NCT00003436
- Testing
- amsacrine, asparaginase, cytarabine
- Where
- United Kingdom
- Volunteers
- 2,000 people
- Sponsor
- Medical Research Council
Breast Cancer, Neutropenia
Intermittent G-CSF in Patients With Breast Cancer Receiving Adjuvant Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)
To compare the efficacy and safety of Day 2 (D2) once a cycle pegfilgrastim with Intermittent Every Other Days of 5 Shot (D3-11) filgrastim in early breast cancer patients treated with adjuvant Docetaxel, Doxorubicin, and…
- Conditions
- Breast Cancer, Neutropenia, Febrile Neutropenia
- Trial name
- NCT02685111
- Testing
- Filgrastim, Peg-filgrastim
- Where
- South Korea
- Volunteers
- 22 people
- Sponsor
- Asan Medical Center
Pediatric Acute Myeloid Leukemia
Home Away From Home - Quality of Life Surveys
Treatment for pediatric acute myeloid leukemia (AML) involves intensive chemotherapy regimens that result in periods of profound neutropenia leaving patients susceptible to severe infectious complications.
- Trial name
- Aim 3 (NCT02777021)
- Where
- 15 sites in United States
- Volunteers
- 154 people, healthy volunteers welcome
- Sponsor
- Children's Hospital of Philadelphia
Leukemia
Drug Biomarkers in Cell Samples From Patients With Acute Myeloid Leukemia
RATIONALE: Studying cell samples from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer PURPOSE: This research study is studying drug…
- Trial name
- NCT01150058
- Testing
- western blotting, flow cytometry, laboratory biomarker analysis
- Volunteers
- 40 people
- Sponsor
- Children's Oncology Group
Solid Tumors, Hematologic Malignancies
A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine
This is an open label, dose escalation study with 3 arms (Arms A, B, and C). Arm A will assess the safety and tolerability of escalating doses of SB939 in cohorts of patients with advanced solid tumors.
- Conditions
- Solid Tumors, Hematologic Malignancies, Myelodysplastic Syndrome
- Trial name
- NCT00741234
- Testing
- SB939, Azacitidine
- Where
- 5 sites in United States, Singapore
- Volunteers
- 85 people
- Sponsor
- S*BIO
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)
This phase II MATCH treatment trial investigates the good and bad effects of binimetinib in patients whose cancer has a genetic change called NRAS mutation.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439344
- Testing
- Binimetinib
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Long-term Effects Secondary to Cancer Therapy in Adults
Ovarian Damage in Young Premenopausal Women Undergoing Chemotherapy for Cancer
RATIONALE: Comparing results of diagnostic procedures, such as ultrasound, done before, during, and after chemotherapy may help doctors learn about the side effects of chemotherapy and help plan the best treatment.
- Conditions
- Leukemia, Long-term Effects Secondary to Cancer Therapy in Adults, Long-term Effects Secondary to Cancer Therapy in Children, Lymphoma
- Trial name
- NCT00402935
- Testing
- laboratory biomarker analysis, fertility assessment and management, management of therapy complications
- Where
- United States
- Sponsor
- Case Comprehensive Cancer Center
Multiple Myeloma
Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients
The purpose of this Phase 1/2 study is to evaluate the efficacy and safety of treatment with VELCADE, dexamethasone, and Revlimid® (VDR) as well as VELCADE, dexamethasone, cyclophosphamide, and Revlimid (VDCR) in patients with…
- Trial name
- EVOLUTION (NCT00507442)
- Testing
- VELCADE (bortezomib), dexamethasone, cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 158 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Leukemia, Lymphoma
Donor Stem Cell Transplant After Conditioning Therapy in Treating Patients With Hematologic Cancer, Recurrent or Metastatic Solid Tumor, or Other Disease
RATIONALE: Giving chemotherapy before a donor stem cell transplant helps stop the growth of cancer or abnormal cells. It also helps stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00521430
- Testing
- anti-thymocyte globulin, busulfan, cyclosporine
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Asan Medical Center
Acute Myeloid Leukemia
Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy
This phase II trial tests how well ziftomenib works in treating patients with NPM1 mutated or KMT2A rearranged acute myeloid leukemia (AML) and are not eligible to receive standard therapy.
- Trial name
- NCT06930352
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Uma Borate
Acute Lymphatic Leukemia, Lymphoma
More Than Just X-Rays - Imaging of Chemotherapy-induced Morphological and Functional Cardiovascular and Lung Changes After Childhood ALL and Other Cancers - a Monocentric Late Effects Study (MaximALL)
In this study, we investigate the cardiopulmonary health of survivors who underwent cancer treatment for acute lymphoblastic leukemia (ALL) or lymphoma during childhood, compared with healthy controls.
- Trial name
- MaximALL (NCT07705178)
- Testing
- QOL assessment, Neuropsychological, Spirometry, DLCO measurement
- Where
- Germany
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- University of Erlangen-Nürnberg Medical School
Chronic Myeloproliferative Disorders, Leukemia
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
RATIONALE: Antiemetic drugs, such as ondansetron, may help to reduce or prevent nausea and vomiting in patients with advanced cancer.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00006348
- Testing
- ondansetron
- Where
- 12 sites in United States
- Volunteers
- 100 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Multiple Myeloma
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer).
- Trial name
- NCT06152575
- Testing
- Elranatamab, Elotuzumab, Pomalidomide
- Where
- 270 sites in United States, Argentina and 25 more
- Volunteers
- 492 people
- Sponsor
- Pfizer
Lymphoma, Solid Tumor
Pemetrexed and Oxaliplatin in Treating Patients With Metastatic Solid Tumors or Lymphoma
RATIONALE: Pemetrexed may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as oxaliplatin, work in different ways to stop the growth of cancer cells, either…
- Trial name
- NCT00470405
- Testing
- oxaliplatin, pemetrexed disodium
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Vanderbilt-Ingram Cancer Center